CytoMed Therapeutics Ltd
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filerEmerging growth company
State of Incorporation
Singapore
Business Address
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, U0, 149544
Mailing Address
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, U0, 149544
Phone
603824911
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | January 28, 2026 | View on SEC |
| 6-K Foreign company current report | January 13, 2026 | View on SEC |
| 6-K Foreign company current report | December 8, 2025 | View on SEC |
| 6-K Foreign company current report | November 18, 2025 | View on SEC |
| 6-K Foreign company current report | November 6, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 29, 2025 | View on SEC |
| 6-K Foreign company current report | October 22, 2025 | View on SEC |
| 6-K Foreign company current report | October 14, 2025 | View on SEC |
Annual Reports
20-F
March 31, 2026
- Pioneering 'cell factory' infrastructure for off-the-shelf cancer therapies.
- Advancing CTM-N2D lead candidate targeting solid tumors.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.